AU2007315402B2 - Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor - Google Patents

Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor Download PDF

Info

Publication number
AU2007315402B2
AU2007315402B2 AU2007315402A AU2007315402A AU2007315402B2 AU 2007315402 B2 AU2007315402 B2 AU 2007315402B2 AU 2007315402 A AU2007315402 A AU 2007315402A AU 2007315402 A AU2007315402 A AU 2007315402A AU 2007315402 B2 AU2007315402 B2 AU 2007315402B2
Authority
AU
Australia
Prior art keywords
csf
subject
sequence identity
fungal
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007315402A
Other languages
English (en)
Other versions
AU2007315402A1 (en
Inventor
Kaare Fiala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drugrecure AS
Original Assignee
Drugrecure AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure AS filed Critical Drugrecure AS
Publication of AU2007315402A1 publication Critical patent/AU2007315402A1/en
Application granted granted Critical
Publication of AU2007315402B2 publication Critical patent/AU2007315402B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2007315402A 2006-11-03 2007-11-02 Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor Active AU2007315402B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86419006P 2006-11-03 2006-11-03
US60/864,190 2006-11-03
US94751107P 2007-07-02 2007-07-02
US60/947,511 2007-07-02
PCT/DK2007/050161 WO2008052567A2 (en) 2006-11-03 2007-11-02 Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor

Publications (2)

Publication Number Publication Date
AU2007315402A1 AU2007315402A1 (en) 2008-05-08
AU2007315402B2 true AU2007315402B2 (en) 2013-05-16

Family

ID=39344625

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007315402A Active AU2007315402B2 (en) 2006-11-03 2007-11-02 Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor

Country Status (8)

Country Link
US (1) US20100015217A1 (enExample)
EP (1) EP2094290B1 (enExample)
JP (3) JP2010508365A (enExample)
AU (1) AU2007315402B2 (enExample)
BR (1) BRPI0717958B8 (enExample)
CA (1) CA2668292C (enExample)
MX (1) MX2009004802A (enExample)
WO (1) WO2008052567A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116470A1 (en) * 2007-03-26 2008-10-02 Drugrecure Aps Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
EP2688583A4 (en) 2011-03-22 2014-10-29 Univ Texas PROTECTION AGAINST INFLUENZA INFECTIONS BY THE GRANULOCYTE MACROPHAGENCOLONIA STIMULATING FACTOR
EP2694093B1 (en) * 2011-04-07 2018-03-21 Reponex Pharmaceuticals ApS Granulocyte-macrophage colony stimulating factor for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation intervention and cancer therapy
JP2014529614A (ja) * 2011-08-29 2014-11-13 トリフォイリウム・エピエス 放射線により誘発されるまたは化学療法により誘発される肺機能不全の治療または予防のための組成物および方法
EP2850176B1 (en) * 2012-05-18 2019-01-16 Syracuse University Controlling pseudomonas aeruginosa persister cells with gm-csf
EP2877199A1 (en) * 2012-07-20 2015-06-03 Trifoilium ApS Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
WO2014096032A1 (en) * 2012-12-18 2014-06-26 Trifoilium Aps Gm-csf for treatment of chronic sinusitis
WO2014128173A1 (en) 2013-02-20 2014-08-28 Trifoilium Aps Gm-csf for treatment of chronic oral mucositis
WO2015110536A1 (en) * 2014-01-22 2015-07-30 Reponex Pharmaceuticals Aps Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma
US20170035850A1 (en) * 2014-03-07 2017-02-09 Reponex Pharmaceuticals Aps Compositions for treating lung infections by airway administration
JP2017524655A (ja) * 2014-05-23 2017-08-31 レポネックス・ファーマシューティカルズ・エーピーエス 創傷の治癒を促進するための組成物
EP3171887A1 (en) 2014-07-24 2017-05-31 Reponex Pharmaceuticals APS Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
JP7545893B2 (ja) * 2017-10-16 2024-09-05 ドラッグレキュア エーピーエス 難治性非結核性マイコバクテリア感染症の治療のためのｇｍ－ｃｓｆ
WO2021188883A1 (en) * 2020-03-20 2021-09-23 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for the treatment of viral disease using granulocyte-macrophage colony-stimulating factor (gm-csf)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US9269067B2 (en) * 2002-04-04 2016-02-23 Altisource Solutions S.À.R.L. Method and apparatus for providing selective access to information
US7512585B2 (en) 2002-07-11 2009-03-31 Oracle International Corporation Support for multiple mechanisms for accessing data stores

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ARAI T., et al., Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF, Respiratory Medicine, 2004, Vol. (98), pages 1227-1230 *
BODEY G., et al, Role of Granulocyte-Macrophage Colony-Stimulating Factor as Adjuvant Therapy for Fungal Infection in Patients with Cancer, Clinical Infectious Diseases, October 1993, Vol. 17(4), pages 705-707 *
BONIFIELD T., et al., Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis, Clinical Immunology, 2002, Vol. 105(3), pg. 342-350 *
BOOTS R., et al, Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF, Thorax, 1999, Vol. 54, pages 1047-1049 *
HUSTINX W, et al., Effect of granulocyte colony stimulating factor (G-CSF) treatment on granulocyte function and receptor expression in patients with ventilator dependent pneumonia, Clin. Exp. Immunol, 1998, Vol. 112, pg. 334-340 *
PRICE A., et al., Pulmonary Alveolar Proteinosis Associated with Anti-GMCSF Antibodies in a Child: Successful Treatment with Inhaled GM-CSF, Pediatric Pulmonology, 2006, Vol. 41, pages 367-370 *
TAZAWA R., et al., Granulocyte-macrophage colony-stimulating factor inhalation therapy for patients with idiopathic pulmonary alveolar proteinosis, Respirology, 2006, Vol. 11 pages S61- S64 *
WYLAM M., et al, Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis, European Respiratory Journal, 2006, Vol. 27(3), pages 585-593 *

Also Published As

Publication number Publication date
JP2014028839A (ja) 2014-02-13
CA2668292C (en) 2018-04-03
EP2094290A2 (en) 2009-09-02
JP2016040300A (ja) 2016-03-24
BRPI0717958B1 (pt) 2019-12-10
BRPI0717958A2 (pt) 2013-11-05
JP2010508365A (ja) 2010-03-18
MX2009004802A (es) 2009-08-12
CA2668292A1 (en) 2008-05-08
EP2094290B1 (en) 2017-07-19
AU2007315402A1 (en) 2008-05-08
WO2008052567A2 (en) 2008-05-08
WO2008052567A3 (en) 2009-01-22
JP6001151B2 (ja) 2016-10-05
BRPI0717958B8 (pt) 2021-05-25
US20100015217A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
AU2007315402B2 (en) Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor
US20130274171A1 (en) Trefoil factors (tff) for the treatment of chronic pulmonary diseases
WO2002085300A2 (en) Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
US20150174204A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
RU2496516C2 (ru) Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути
HK1135911B (en) Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor
HK1135911A (en) Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor
WO2008116470A1 (en) Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
JP7545893B2 (ja) 難治性非結核性マイコバクテリア感染症の治療のためのｇｍ－ｃｓｆ
MX2007016372A (es) Administracion a las vias respiratorias de la proteina c activada en condiciones inflamatorias que afectan el tracto respiratorio
MX2007016370A (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
WO2015110536A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma
HK1114567B (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)